Mouse models for the study of mucosal vaccination against otitis media

Vaccine

Volumn 26, Issue 12, 2008, Pages 1501-1524

  Sabirov, Albert ^a   Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Mouse; Mucosal; Otitis media; Review; Vaccination

Indexed keywords

BACTERIAL VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE; LIVE VACCINE; PARAINFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TETANUS TOXOID; VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; CELLULAR IMMUNITY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLAMMATION; INNATE IMMUNITY; INOCULATION; MORAXELLA CATARRHALIS; MUCOSAL IMMUNITY; NONHUMAN; NOSE CAVITY; OTITIS MEDIA; PARAINFLUENZA VIRUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; MICE; OTITIS MEDIA; VACCINES;

EID: 40049088170     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.029     Document Type: Review

References (212)

1. Moyle P.M., McGeary R.P., Blanchfield J.T., and Toth I. Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv 1 4 (2004) 385-396
2. Krekorian T.D., Keithley E.M., Fierer J., and Harris J.P. Type B Haemophilus influenzae-induced otitis media in the mouse. Laryngoscope 101 6 Pt 1 (1991) 648-656
3. Melhus A., and Ryan A.F. A mouse model for acute otitis media. APMIS 111 10 (2003) 989-994
4. Bikhazi P., and Ryan A.F. Expression of immunoregulatory cytokines during acute and chronic middle ear immune response. Laryngoscope 105 6 (1995) 629-634
5. Johnson M., Leonard G., and Kreutzer D.L. Murine model of interleukin-8-induced otitis media. Laryngoscope 107 10 (1997) 1405-1408
6. Ogra P.L., Faden H., and Welliver R.C. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14 2 (2001) 430-445
7. Lim D.J. Functional morphology of the lining membranes of the middle ear and Eustachian tube. An overview. Ann Otol Rhinol Laryngol 83 Suppl. 11 (1974) 5-22
8. Ichimiya I., Kawauchi H., and Mogi G. Analysis of immunocompetent cells in the middle ear mucosa. Arch Otolaryngol Head Neck Surg 116 3 (1990) 324-330
9. Heikkinen T., Ruuskanen O., Waris M., Ziegler T., Arola M., and Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 145 4 (1991) 445-448
10. Russell F., and Mulholland K. Prevention of otitis media by vaccination. Drugs 62 10 (2002) 1441-1445
11. Kurono Y., Lim D.J., and Mogi G. Middle ear and eustachian tube. In: Mestecky J., Lamm M.E., McGhee J.R., Bienenstock J., Mayer L., and Strober W. (Eds). Mucosal immunology. 3rd ed. (2005), Academic Press, New York 1509-1516
12. Gu X.X., Rudy S.F., Chu C., McCullagh L., Kim H.N., Chen J., et al. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine 21 17/18 (2003) 2107-2114
13. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 9512 (2006) 740-748
14. Pelton S.I. Vaccination for the prevention of acute otitis media: proof of concept and current challenges. Pediatr Ann 31 12 (2002) 804-809
15. Harrison C.J. Changes in treatment strategies for acute otitis media after full implementation of the pneumococcal seven valent conjugate vaccine. Pediatr Infect J 22 Suppl. 8 (2003) S120-S130
16. Shinefield H.R., and Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 19 4 (2000) 394-397
17. Holmgren J., Czerkinsky C., Eriksson K., and Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 Suppl. 2 (2003) S89-S95
18. Robbins J.B., Schneerson R., and Szu S.C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171 6 (1995) 1387-1398
19. Zuercher A.W. Upper respiratory tract immunity. Viral Immunol 16 3 (2003) 279-289
20. van Ginkel F.W., Nguyen H.H., and McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 6 2 (2000) 123-132
21. Russell M.W., and Kilian M. Biological activities of IgA. In: Mestecky J., Lamm M.E., Strober W., Bienenstock J., McGhee J.R., and Mayer L. (Eds). Mucosal immunology. 3rd ed. (2005), Academic Press, London 267-290
22. Debertin A.S., Tschernig T., Tönjes H., Kleemann W.J., Tröger H.D., and Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin Exp Immunol 134 3 (2003) 503-507
23. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 13 6 (1992) 219-224
24. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 2 (2006) 148-158
25. Russell M.W., Martin M.H., Wu H.Y., Hollingshead S.K., Moldoveanu Z., and Mestecky J. Strategies of immunization against mucosal infections. Vaccine 19 Suppl. 1 (2000) S122-S127
26. Csencsits K.L., Walters N., and Pascual D.W. Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: alpha(E) versus l-selectin. J Immunol 167 5 (2001) 2441-2445
27. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74 (1993) 185
28. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanarman V.S., Wassef N.M., Alving C.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160 (1998) 2000
29. Bergquist C., Johansson E.L., Lagergard T., Holmgren J., and Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 65 (1997) 2672
30. Rudin A., Johansson E.-L., Berquist C., and Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66 (1998) 3390
31. MacPherson G.G., and Liu L.M. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr Top Microbiol Immunol 236 (1999) 33-35
32. Kunkel E.J., and Butcher E.C. Plasma-cell homing. Nat Rev Immunol 3 10 (2003) 822-829
33. Nugent J., Po A.L., and Scott E.M. Design and delivery of non-parenteral vaccines. J Clin Pharm Ther 23 4 (1998) 257-285
34. Boyaka P.N., McGhee J.R., Czerkinsky C., and Mestecky J. Mucosal vaccines: an overview. In: Mestecky J., Lamm M.E., Strober W., Bienenstock J., McGhee J.R., and Mayer L. (Eds). Mucosal immunology. 3rd ed. (2005), Academic Press, London 855-874
35. Boyaka P.N., Marinaro M., Jackson R.J., Menon S., Kiyono H., Jirillo E., et al. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 162 1 (1999) 122-128
36. Arulanandam B.P., Van Cleave V.H., and Metzger D.W. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol 29 1 (1999) 256-264
37. Coffman R.L., Seymour B.W., Lebman D.A., Hiraki D.D., Christiansen J.A., Shrader B., et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 102 (1988) 5-28
38. Yanagita M., Hiroi T., Kitagaki N., Hamada S., Ito H.O., Shimauchi H., et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 162 6 (1999) 3559-3565
39. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 2 (1992) 75-88
40. Hiroi T., Iwatani K., Iijima H., Kodama S., Yanagita M., and Kiyono H. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur J Immunol 28 10 (1998) 3346-3353
41. Jecker P., Pabst R., and Westermann J. Proliferating macrophages, dendritic cells, natural killer cells, T and B lymphocytes in the middle ear and Eustachian tube mucosa during experimental acute otitis media in the rat. Clin Exp Immunol 126 3 (2001) 421-425
42. Takahashi M., Kanai N., Watanabe A., Oshima O., and Ryan A.F. Lymphocyte subsets in immune-mediated otitis media with effusion. Eur Arch Otorhinolaryngol 249 1 (1992) 24-27
43. Kodama S., Hirano T., Suenaga S., Abe N., and Suzuki M. Eustachian tube possesses immunological characteristics as a mucosal effector site and responds to P6 outer membrane protein of nontypeable Haemophilus influenzae. Vaccine 24 7 (2006) 1016-1027
44. Kodama S., Suenaga S., Hirano T., Suzuki M., and Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 68 4 (2000) 2294-2300
45. Sabirov A., and Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24 27/28 (2006) 5584-5592
46. Kurono Y., Mogi G., Kodama S., Yamamoto M., McGhee J.R., and Kiyono H. Mucosal immune responses in mice immunized intranasally with outer membrane proteins of Haemophilus influenzae. Abstracts of the 9th international congress of mucosal immunology. Sydney, Australia (1997) 28
47. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., and Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6 5 (1988) 409-413
48. McCluskie M.J., and Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19 4/5 (2000) 413-422
49. Doyle W.J. Animal models of otitis media: other pathogens. Pediatr Infect Dis J 8 Suppl. 1 (1989) S45-S47
50. Giebink G.S. Otitis media: the chinchilla model. Microb Drug Resist 5 1 (1999) 57-72
51. Means L.W., Daniel H.J., Jordan L.H., and Loesche P.J. Nonsusceptibility to otitis media of the laboratory gerbil. Meriones unguiculatus. Physiol Psychol 3 (1975) 229-230
52. Thompson T.A., Gardner D., Fulghum R.S., Daniel H.J., Allen W.E., Worthington J.M., et al. Indigenous nasopharyngeal, auditory canal, and middle ear bacterial flora of gerbils: animal model for otitis media. Infect Immun 32 3 (1981) 1113-1118
53. Takoudes T.G., and Haddad Jr. J. Hydrogen peroxide in acute otitis media in guinea pigs. Laryngoscope 107 2 (1997) 206-210
54. Cook R.D., Postma D.S., Brinson G.M., Prazma J., and Pillsbury H.C. Cytotoxic changes in hair cells secondary to pneumococcal middle-ear infection. J Otolaryngol 28 6 (1999) 325-331
55. Sato K. Experimental otitis media induced by nonviable Moraxella catarrhalis in the guinea pig model. Auris Nasus Larynx 24 3 (1997) 233-238
56. Yoshimura H., Watanabe N., Bundo J., Shinoda M., and Mogi G. Oral vaccine therapy for pneumococcal otitis media in an animal model. Arch Otolaryngol Head Neck Surg 117 8 (1991) 889-894
57. Wells J.R., Gernon W.H., Ward G., Davis R.K., and Hays L.L. Otosurgical model in the guinea pig (Cavia porcellus). Otolaryngol Head Neck Surg 95 4 (1986) 450-457
58. Daniel H.J., Carmine F.H., and Cook R.A. Otitis media in two strains of laboratory rats. J Aud Res 11 (1971) 276-278
59. Daniel H.J., Means L.W., Dressel M.E., and Loesche P.J. Otitis media in laboratory rats. Physiol Psychol 1 (1973) 7-8
60. Sabirov A., Kodama S., Hirano T., Suzuki M., and Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 69 5 (2001) 2964-2971
61. Ichimiya I., Suzuki M., Hirano T., and Mogi G. The influence of pneumococcal otitis media on the cochlear lateral wall. Hear Res 131 1/2 (1999) 128-134
62. Committee on Infectious Diseases of Mice and Rats, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Infectious Diseases of Mice and Rats (1991), The National Academic Press, Washington, DC
63. Hellmstrom S., Salen B., and Stenfors L.E. Anatomy of the rat middle ear. A study under the dissection microscope. Acta Anat (Basel) 112 (1982) 346-352
64. Foxwell A.R., Kyd J.M., and Cripps A.W. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev 62 2 (1998) 294-308
65. Westman E. Animal models for studies of middle ear pathology. In: Experimental acute otitis media. Aspects on treatment, protection and structural changes (Thesis, Umea University, Sweden). Sundsvall, Kaltes Grafiska AB; 2003. p. 19-20.
66. Daniel III H.J., Fulghum R.S., Brinn J.E., and Barrett K.A. Comparative anatomy of eustachian tube and middle ear cavity in animal models for otitis media. Ann Otol Rhinol Laryngol 91 1 Pt 1 (1982) 82-89
67. Zheng Q.Y., Hardisty-Hughes R., and Brown S.D. Mouse models as a tool to unravel the genetic basis for human otitis media. Brain Res 1091 1 (2006) 9-15
68. Lim D.J., Hermansson A., Hellström S.O., Hussl B., Alper C.M., Iino Y., et al. Recent advances in otitis media. 3. Animal models; anatomy and pathology; pathogenesis; cell biology and genetics. Ann Otol Rhinol Laryngol 194 Suppl. (2005) 31-41
69. Trune D.R. Mouse models for immunologic diseases of the auditory system. In: Willott J.F. (Ed). Handbook of mouse auditory research: from behavior to molecular biology (2001), CRC Press, Boca Raton 505-531
70. McGinn M.D., Bean-Knudsen D., and Ermel R.W. Incidence of otitis media in CBA/J and CBA/CaJ mice. Hear Res 59 1 (1992) 1-6
71. Malley R., Morse S.C., Leite L.C., Areas A.P., Ho P.L., Kubrusly F.S., et al. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72 7 (2004) 4290-4292
72. McCool T.L., and Weiser J.N. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun 72 10 (2004) 5807-5813
73. McCool T.L., Cate T.R., Tuomanen E.I., Adrian P., Mitchell T.J., and Weiser J.N. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 71 10 (2003) 5724-5732
74. Ryan A.F., Ebmeyer J., Furukawa M., Pak K., Melhus A., Wasserman S.I., et al. Mouse models of induced otitis media. Brain Res 1091 1 (2006) 3-8
75. McCullers J.A., Karlstrom A., Iverson A.R., Loeffler J.M., and Fischetti V.A. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3 3 (2007) 28
76. Sabirov A., and Metzger D.W. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 26 12 (2008) 1566-1576
77. Bertot G.M., Becker P.D., Guzman C.A., and Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 189 7 (2004) 1304-1312
78. Meek III R.B., McGrew B.M., Cuff C.F., Berrebi A.S., Spirou G.A., and Wetmore S.J. Immunologic and histologic observations in reovirus-induced otitis media in the mouse. Ann Otol Rhinol Laryngol 108 1 (1999) 31-38
79. Hirano T., Tomiguchi M., Mabuchi H., Kodama S., and Suzuki M. Analysis of the cellular immune responses to influenza a virus infection in the middle ear. Abstracts of the 9th international symposium on recent advances in otitis media. St. Pete Beach, FA, USA (2007) 104
80. Hirano T., Kurono Y., Ichimiya I., Suzuki M., and Mogi G. Effects of influenza A virus on lectin-binding patterns in murine nasopharyngeal mucosa and on bacterial colonization. Otolaryngol Head Neck Surg 121 5 (1999) 616-621
81. Francis T.E., and de Torregrosa M.V. Combined infection of mice with H. influenzae and influenza virus by the intranasal route. J Infect Dis 76 (1945) 70-77
82. McCullers J.A., and Regh J.E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186 3 (2002) 341-350
83. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19 3 (2006) 571-582
84. Gitiban N., Jurcisek J.A., Harris R.H., Mertz S.E., Durbin R.K., Bakaletz L.O., et al. Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus. J Virol 79 10 (2005) 6035-6042
85. Domachowske J.B., Bonville C.A., and Rosenberg H.F. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr Infect Dis J 23 Suppl. 11 (2004) S228-S234
86. Appell L.H., Kovatch R.M., Reddecliff J.M., and Gerone P.J. Pathogenesis of Sendai virus infection in mice. Am J Vet Res 32 11 (1971) 1835-1841
87. Faisca P., and Desmecht D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Res Vet Sci 82 1 (2007) 115-125
88. Klemens J.J., Thompson K., Langerman A., and Naclerio R.M. Persistent inflammation and hyperresponsiveness following viral rhinosinusitis. Laryngoscope 116 7 (2006) 1236-1240
89. Hirano T., Kodama S., Fujita K., Maeda K., and Suzuki M. Role of Toll-like receptor 4 in innate immune responses in a mouse model of acute otitis media. FEMS Immunol Med Microbiol 49 1 (2007) 75-83
90. McCoy S.L., Kurtz S.E., Macarthur C.J., Trune D.R., and Hefeneider S.H. Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation. J Immunol 174 5 (2005) 3006-3014
91. MacArthur C.J., Hefeneider S.H., Kempton J.B., Parrish S.K., McCoy S.L., and Trune D.R. Evaluation of the mouse model for acute otitis media. Hear Res 219 1/2 (2006) 12-23
92. van Rossum A.M., Lysenko E.S., and Weiser J.N. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 73 11 (2005) 7718-7726
93. Harford C.G., Leidler V., and Hara M. Effect of the lesion due to influenza virus on the resistance of mice to inhaled pneumococci. J Exp Med 89 (1949) 53-67
94. Wu H.Y., Virolainen A., Mathews B., King J., Russell M.W., and Briles D.E. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 23 3 (1997) 127-137
95. Briles D.E., Novak L., Hotomi M., van Ginkel F.W., and King J. Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73 10 (2005) 6945-6951
96. Sun K., Johansen F.E., Eckmann L., and Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173 7 (2004) 4576-4581
97. Hodge L.M., Marinaro M., Jones H.P., McGhee J.R., Kiyono H., Simecka J.W., et al. (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun 69 4 (2001) 2328-2338
98. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73 10 (2005) 6892-6902
99. Zheng Q.Y., Tong Y.C., Alagramam K.N., and Yu H. Tympanometry assessment of 61 inbred strains of mice. Hear Res 231 1/2 (2007) 23-31
100. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168 6 (2002) 2930-2938
101. Lynch J.M., Briles D.E., and Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71 8 (2003) 4780-4788
102. Trzcinski K., Thompson C., Malley R., and Lipsitch M. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun 73 10 (2005) 7043-7046
103. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 (2005) 4848-4853
104. Roche A.M., King S.J., and Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 75 5 (2007) 2469-2475
105. Hardistry R.E., Erven A., Logan K., Morse S., Guionaud S., Sancho-Oliver S., et al. The deaf mouse mutant Jeff (Jf) is a single gene model of otitis media. J Assoc Res Otolaryngol 4 (2003) 130-138
106. Hardisty-Hughes R.E., Tateossian H., Morse S.A., Romero M.R., Middleton A., Tymowska-Lalanne Z., et al. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum Mol Genet 15 22 (2006) 3273-3279
107. Parkinson N., Hardisty-Hughes R.E., Tateossian H., Tsai H.T., Brooker D., Morse S., et al. Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media. PLoS Genet 2 10 (2006) e149
108. Hotomi M., Yamanaka N., Shimada J., Suzumoto M., Ikeda Y., Sakai A., et al. Intranasal immunization with recombinant outer membrane protein P6 induces specific immune responses against nontypeable Haemophilus influenzae. Int J Pediatr Otorhinolaryngol 65 2 (2002) 109-116
109. Abe N., Kodama S., Hirano T., Eto M., and Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope 116 3 (2006) 407-412
110. Mason K.W., Zhu D., Scheuer C.A., McMichael J.C., Zlotnick G.W., and Green B.A. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine 22 25/26 (2004) 3449-3456
111. Hotomi M., Ikeda Y., Suzumoto M., Yamauchi K., Green B.A., Zlotnick G., et al. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine 23 10 (2005) 1294-1300
112. Cutter D., Mason K.W., Howell A.P., Fink D.L., Green B.A., and St Geme III J.W. Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. J Infect Dis 186 2 (2002) 1115-1121
113. Hirano T., Hou Y., Jiao X., and Gu X.X. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 35 1 (2003) 1-10
114. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 69 8 (2001) 4870-4873
115. Oliveira M.L., Arêas A.P., Campos I.B., Monedero V., Perez-Martínez G., Miyaji E.N., et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 8 4 (2006) 1016-1024
116. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., and Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175 4 (1997) 839-846
117. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18 16 (2000) 1707-1711
118. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 2 (2000) 796-800
119. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., and Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69 11 (2001) 6718-6724
120. Balachandran P., Brooks-Walter A., Virolainen-Julkunen A., Hollingshead S.K., and Briles D.E. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70 5 (2002) 2526-2534
121. Tanaka N., Fukuyama S., Fukuiwa T., Kawabata M., Sagara Y., Ito H.O., et al. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine 25 14 (2007) 2680-2687
122. Green B.A., Zhang Y., Masi A.W., Barniak V., Wetherell M., Smith R.P., et al. PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 73 2 (2005) 981-989
123. Zhang Y., Masi A.W., Barniak V., Mountzouros K., Hostetter M.K., and Green B.A. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 69 6 (2001) 3827-3836
124. Malley R., Srivastava A., Lipsitch M., Thompson C.M., Watkins C., Tzianabos A., et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74 4 (2006) 2187-2195
125. Renegar K.B., and Small Jr. P.A. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol 65 4 (1991) 2146-2148
126. Tamura S.I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22 2 (1992) 477-481
127. Tamura S., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 149 3 (1992) 981-988
128. Tamura S., Asanuma H., Ito Y., Yoshizawa K., Nagamine T., Aizawa C., et al. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine 12 4 (1994) 310-316
129. Asanuma H., Koide F., Suzuki Y., Nagamine T., Aizawa C., Kurata T., et al. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine 13 1 (1995) 3-5
130. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8 3 (1990) 243-248
131. Watanabe I., Hagiwara Y., Kadowaki S.E., Yoshikawa T., Komase K., Aizawa C., et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20 29/30 (2002) 3443-3455
132. de Haan A., Geerligs H.J., Huchshorn J.P., van Scharrenburg G.J., Palache A.M., and Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13 2 (1995) 155-162
133. de Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19 20-22 (2001) 2898-2907
134. Davis S.S. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24 Suppl. 2 (2006) S2/7-S2/10
135. Valosky J., Hishiki H., Zaoutis T.E., and Coffin S.E. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol 12 1 (2005) 171-179
136. Walsh E.E. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 170 2 (1994) 345-350
137. Oien N.L., Brideau R.J., Walsh E.E., and Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12 8 (1994) 731-735
138. Nedrud J.G., Liang X.P., Hague N., and Lamm M.E. Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol 139 10 (1987) 3484-3492
139. Takao S.I., Kiyotani K., Sakaguchi T., Fujii Y., Seno M., and Yoshida T. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. J Virol 71 1 (1997) 832-838
140. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 1-3 (2001) 21-42
141. Giebink G.S., Kurono Y., Bakaletz L.O., Kyd J.M., Barenkamp S.J., Murphy T.F., et al. Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol 194 Suppl. (2005) 86-103
142. Kurono Y., Shimamura K., and Mogi G. Inhibition of nasopharyngeal colonization of Haemophilus influenzae by oral immunization. Ann Otol Rhinol Laryngol 157 (1992) 11-15
143. Kurono Y., Shigemi H., Kodama S., and Mogi G. Effects of oral and systemic immunization on nasopharyngeal clearance of nontypeable Haemophilus influenzae in BALB/c mice. Laryngoscope 106 5 Pt 1 (1996) 614-618
144. Suzuki M., Kurono Y., Kodama S., Shigemi H., and Mogi G. Enhancement of nasal clearance of nontypeable Haemophilus influenzae by oral immunization with outer membrane proteins. Acta Otolaryngol 118 6 (1998) 864-869
145. Hotomi M., Saito T., and Yamanaka N. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin. Vaccine 16 20 (1998) 1950-1956
146. Kurono Y., Yamamoto M., Fujihashi K., Kodama S., Suzuki M., Mogi G., et al. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 180 1 (1999) 122-132
147. Hirano T., Jiao X., Chen Z., Van Waes C., and Gu X.X. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol Lett 107 2 (2006) 131-139
148. Kodama S., Abe N., Hirano T., and Suzuki M. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope 116 2 (2006) 331-335
149. Yamauchi K., Hotomi M., Billal D.S., Suzumoto M., and Yamanaka N. Maternal intranasal immunization with outer membrane protein P6 maintains specific antibody level of derived offspring. Vaccine 24 25 (2006) 5294-5299
150. Kodama S., Hirano T., Abe N., and Suzuki M. A single nasal dose of Flt3 ligand enhances mucosal immune responses in the nasopharynx. Abstracts of the 9th international symposium on recent advances in otitis media. St. Pete Beach, FA (2007) 71
151. Barenkamp S.J. Rationale and prospects for a nontypeable Haemophilus influenzae vaccine. Pediatr Infect Dis J 23 5 (2004) 461-462
152. Katsurahara T., Hotomi M., Yamauchi K., Suzumoto M., Billal D., Briles D., et al. Protection of pneumococcal infection by maternal immunization with pneumococcal surface protein a (PspA). Abstracts of the 9th international symposium on recent advances in otitis media. St. Pete Beach, FA (2007) 112
153. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 32 3 (2006) 139-153
154. Hou Y., Hu W.G., Hirano T., and Gu X.X. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 20 17/18 (2002) 2375-2381
155. Jiao X., Hirano T., Hou Y., and Gu X.X. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 70 11 (2002) 5982-5989
156. Lövgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 27 2 (1988) 241-245
157. Lövgren K., Kåberg H., and Morein B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 82 3 (1990) 435-439
158. Bergmann K.C., and Waldman R.H. Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine). Int Arch Allergy Appl Immunol 87 3 (1988) 334-335
159. el Guink N., Kris R.M., Goodman-Snitkoff G., Small P.A., and Mannino R.J. Intranasal immunization with proteoliposomes protects against influenza. Vaccine 7 2 (1989) 147-151
160. Moldoveanu Z., Novak M., Huang W.Q., Gilley R.M., Staas J.K., Schafer D., et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 167 1 (1993) 84-90
161. Ben Ahmeida E.T., Gregoriadis G., Potter C.W., and Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 11 13 (1993) 1302-1309
162. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12 5 (1994) 419-426
163. Mbawuike I.N., Pacheco S., Acuna C.L., Switzer K.C., Zhang Y., and Harriman G.R. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol 162 5 (1999) 2530-2537
164. Zhang Y., Pacheco S., Acuna C.L., Switzer K.C., Wang Y., Gilmore X., et al. Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus. Immunology 105 3 (2002) 286-294
165. Reuman P.D., Keely S.P., and Schiff G.M. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus. J Med Virol 32 1 (1990) 67-72
166. Trudel M., Nadon F., Séguin C., Brault S., Lusignan Y., and Lemieux S. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10 2 (1992) 107-112
167. Hishiki H., Zuercher A.W., Valosky J., and Coffin S.E. Regional differences in the early mucosal immune response induced by primary inoculation of mice with respiratory syncytial virus. Microb Pathog 36 3 (2004) 141-146
168. Etchart N., Baaten B., Andersen S.R., Hyland L., Wong S.Y., and Hou S. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 36 5 (2006) 1136-1144
169. Hu K.F., Elvander M., Merza M., Akerblom L., Brandenburg A., and Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 113 2 (1998) 235-243
170. Bastien N., Trudel M., and Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17 7/8 (1999) 832-836
171. Tebbey P.W., Unczur C.A., LaPierre N.A., and Hancock G.E. A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol 12 (1999) 41-45
172. Tebbey P.W., Scheuer C.A., Peek J.A., Zhu D., LaPierre N.A., Green B.A., et al. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18 24 (2000) 2723-2734
173. Kim H.J., Kim J.K., Seo S.B., Lee H.J., and Kim H.J. Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus. Arch Pharm Res 30 3 (2007) 366-371
174. Cyr S.L., Jones T., Stoica-Popescu I., Brewer A., Chabot S., Lussier M., et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 25 29 (2007) 5378-5389
175. Smith F.S., Portner A., Leggiadro R.J., Turner E.V., and Hurwitz J.L. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 205 2 (1994) 453-461
176. Sangster M., Smith F.S., Coleclough C., and Hurwitz J.L. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection. Virology 212 1 (1995) 13-19
177. Macpherson A.J., Lamarre A., Mccoy K., Harriman G.R., Odermatt B., Dougan G., et al. IgA production without mu or delta chain expression in developing B cells. Nat Immunol 2 7 (2001) 625-631
178. Boyaka P.N., McGhee J.R., Czerkinsky C., and Mestecky J. Mucosal vaccines: an overview. In: Mestecky J., Lamm M.E., McGhee J.R., Bienenstock J., Mayer L., and Strober W. (Eds). Mucosal immunology. 3rd ed. (2005), Academic Press, New York 855-874
179. Liang X.P., Lamm M.E., and Nedrud J.G. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol 141 5 (1988) 1495-1501
180. Jakobsen H., Schulz D., Pizza M., Rappuoli R., and Jónsdóttir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 67 11 (1999) 5892-5897
181. Lee C.J., Lee L.H., and Frasch C.E. Protective immunity of pneumococcal glycoconjugates. Crit Rev Microbiol 29 4 (2003) 333-349
182. Johnson S.E., Dykes J.K., Jue D.L., Sampson J.S., Carlone G.M., and Ades E.W. Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin a. J Infect Dis 185 4 (2002) 489-496
183. McGhee J.R., Lamm M.E., and Strober W. Mucosal immune responses: an overview. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., and McGhee J.R. (Eds). Mucosal immunology. 2nd ed. (1999), Academic Press, London 485-506
184. Tamura S., Tanimoto T., and Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58 4 (2005) 195-207
185. Renegar K.B., Small Jr. P.A., Boykins L.G., and Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173 3 (2004) 1978-1986
186. Takase H., Murakami Y., Endo A., and Ikeuchi T. Antibody responses and protection in mice immunized orally against influenza virus. Vaccine 14 17/18 (1996) 1651-1656
187. Tamura S., Funato H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., et al. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 21 6 (1991) 1337-1344
188. Weltzin R., Hsu S.A., Mittler E.S., Georgakopoulos K., and Monath T.P. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother 38 12 (1994) 2785-2791
189. Freihorst J., and Ogra P.L. Mucosal immunity and viral infections. Ann Med 33 3 (2001) 172-177
190. Huber V.C., Lynch J.M., Bucher D.J., Le J., and Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166 12 (2001) 7381-7388
191. Takimoto T., Hurwitz J.L., Zhan X., Krishnamurthy S., Prouser C., Brown B., et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 18 2 (2005) 255-266
192. Takimoto T., Hurwitz J.L., Coleclough C., Prouser C., Krishnamurthy S., Zhan X., et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 78 11 (2004) 6043-6047
193. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., and Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159 (1997) 105-117
194. Girard M.P., Cherian T., Pervikov Y., and Kieny M.P. A review of vaccine research and development: human acute respiratory infections. Vaccine 23 50 (2005) 5708-5724
195. Mackenzie C.D., Taylor P.M., and Askonas B.A. Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunology 67 3 (1989) 375-381
196. Lightman S., Cobbold S., Waldmann H., and Askonas B.A. Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology 62 1 (1987) 139-144
197. Epstein S.L., Lo C.Y., Misplon J.A., and Bennink J.R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160 1 (1998) 322-327
198. Benton K.A., Misplon J.A., Lo C.Y., Brutkiewicz R.R., Prasad S.A., and Epstein S.L. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol 166 12 (2001) 7437-7445
199. Metzger D.W. IgA and respiratory immunity. In: Kaetzel A.C.S. (Ed). Mucosal immune defense: immunoglobulin (2007), Plenum Publishers, New York 269-290
200. Koskela M. Antibody response of young children to parenteral vaccination with pneumococcal capsular polysaccharides: a comparison between antibody levels in serum and middle ear effusion. Pediatr Infect Dis 5 4 (1986) 431-434
201. Russell-Jones G.J. Oral vaccine delivery. J Control Release 65 1/2 (2000) 49-54
202. Kaiserlian D., and Etchart N. Epicutaneous and transcutaneous immunization using DNA or proteins. Eur J Dermatol 9 3 (1999) 169-176
203. Foss D.L., and Murtaugh M.P. Mechanisms of vaccine adjuvanticity at mucosal surfaces. Anim Health Res Rev 1 1 (2000) 3-24
204. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 17-19 (2001) 2534-2541
205. Lee C.J., Lee L.H., and Gu X.X. Mucosal immunity induced by pneumococcal glycoconjugate. Crit Rev Microbiol 31 3 (2005) 137-144
206. Mercenier A., Müller-Alouf H., and Grangette C. Lactic acid bacteria as live vaccines. Curr Issues Mol Biol 2 1 (2000) 17-25
207. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 25/26 (2001) 3331-3346
208. Murphy T.F. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 4 6 (2005) 843-853
209. Doherty P.C., Turner S.J., Webby R.G., and Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 7 5 (2006) 449-455
210. Tu Le N., Jeong H.Y., Kwon H.Y., Ogunniyi A.D., Paton J.C., Pyo S.N., et al. Modulation of adherence, invasion, and tumor necrosis factor alpha secretion during the early stages of infection by Streptococcus pneumoniae ClpL. Infect Immun 75 6 (2007) 2996-3005
211. Silin D.S., Lyubomska O.V., Jirathitikal V., and Bourinbaiar A.S. Oral vaccination: where we are?. Expert Opin Drug Deliv 4 4 (2007) 323-340
212. De Magistris M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58 1 (2006) 52-67